Myocardial Infarction Genetics Consortium*
We conducted a genome-wide association study testing single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) for association with early-onset myocardial infarction in 2,967 cases and 3,075 controls. We carried out replication in an independent sample with an effective sample size of up to 19, 492 . SNPs at nine loci reached genome-wide significance: three are newly identified (21q22 near MRPS6-SLC5A3-KCNE2, 6p24 in PHACTR1 and 2q33 in WDR12) and six replicated prior observations [1] [2] [3] [4] (9p21, 1p13 near CELSR2-PSRC1-SORT1, 10q11 near CXCL12, 1q41 in MIA3, 19p13 near LDLR and 1p32 near PCSK9). We tested 554 common copy number polymorphisms (41% allele frequency) and none met the pre-specified threshold for replication (P o 10 À3 ). We identified 8,065 rare CNVs but did not detect a greater CNV burden in cases compared to controls, in genes compared to the genome as a whole, or at any individual locus. SNPs at nine loci were reproducibly associated with myocardial infarction, but tests of common and rare CNVs failed to identify additional associations with myocardial infarction risk.
Myocardial infarction is a leading cause of death and disability worldwide 5 , with family history being an independent risk factor 6 . The inherited basis for myocardial infarction remains incompletely understood. Whereas the majority of myocardial infarctions occur in individuals 465 y old, 1-5% of younger individuals report a history of myocardial infarction 5, 7 . These latter events are associated with substantially greater heritability 8 . Thus, early-onset myocardial infarction is a promising phenotype for genetic mapping.
Genome-wide association studies (GWASs) of common SNPs have been reported for myocardial infarction and coronary artery disease (CAD), with each study finding common SNPs on chromosome 9p21.3 associated with myocardial infarction or CAD [1] [2] [3] . In addition to 9p21.3, Samani et al. reported six other loci as harboring SNPs associated with CAD 3 . Some of these loci await definitive replication, but even if all were valid, they would explain a small fraction of the risk for myocardial infarction.
Structural variants, another class of human DNA sequence variation, may account for some of the unexplained heritability in myocardial infarction and other common diseases 9 . To our knowledge, no integrated assessment of SNPs and CNVs in the same samples has been reported for myocardial infarction or any other trait. Several technological developments make such systematic surveys now possible, including hybrid oligonucleotide microarrays 10 and analytical methods 11 The design called for all variants with a P o 0.001 to be taken forward to stage 2. As only SNPs met this criterion, 1,441 SNPs were taken forward to stage 2. Thirty-three SNPs were tested in stage 3. Thirteen SNPs were tested in stage 4. Statistical evidence for association was combined across stages 1-4 using meta-analysis.
We designed a four-stage GWAS of early-onset myocardial infarction with SNPs, common copy number polymorphisms (CNPs) and rare CNVs (Fig. 1) . Stage 1 consisted of the Myocardial Infarction Genetics Consortium (MIGen), a collection of 2,967 cases of earlyonset myocardial infarction (in men r50 y old or women r60 y old) and 3,075 age-and sex-matched controls free of myocardial infarction from six international sites: Boston and Seattle in the United States, as well as Sweden, Finland, Spain and Italy (Table 1 and Supplementary Methods online). The mean age at the time of myocardial infarction was 41 y among males and 47 y among females. Variants with P o 0.001 were advanced through three stages of replication ( Fig. 1 ; see Methods for power calculations). Descriptions of the replication studies are provided in Supplementary Methods and Supplementary Tables 1 and 2 online.
After stages 1-4, we observed that SNPs at nine loci were associated with myocardial infarction at a pre-specified threshold for genomewide significance of P o 5 Â 10 À8 (corresponding to P o 0.05 after adjusting for B1 million independent tests 12 ) ( Tables 2 and 3) . Of these nine, four represent confirmation of associations previously reported by Samani et al. 3 (Table 2 ). These four genetic association signals map to 9p21, 1p13 near CELSR2-PSRC1-SORT1, 10q11 near CXCL12 and 1q41 in MIA3. In samples fully independent of the two original discovery studies (Wellcome Trust Case Control Consortium and German MI Family Study I), the statistical evidence for these four variants was robust, with the same allele associated in the same direction as the original report (replication P ranging from 3 Â 10 À5 to 1 Â 10 À30 ; Table 2 ).
Three of the loci previously suggested by Samani et al. did not replicate ( Table 2 ). In samples independent of the two original discovery studies, the statistical evidence for these loci was the following: rs6922269 in MTHFD1L (OR ¼ 1.04, 95% CI ¼ 0.99-1.09, P ¼ 0.08); rs17228212 in SMAD3 (OR ¼ 1.01, 95% CI ¼ 0.96-1.05, P ¼ 0.69) and rs2943634 on 2q36 (OR ¼ 0.94, 95% CI ¼ 0.90-0.98, P ¼ 0.01).
Three previously unreported associations were observed with genome-wide significance ( 
MRPS6 encodes a subunit of the mitochondrial ribosomal protein 28S 13 . SLC5A3 is a gene embedded within MRPS6 and encodes a protein that transports sodium and myo-inositol in response to hypertonic stress 14 . KCNE2 encodes a subunit of a potassium channel, and mutations in this gene cause inherited arrhythmias 15 . PHACTR1 is an inhibitor of protein phosphatase 1, an enzyme that dephosphorylates serine and threonine residues on a range of proteins 16 . WDR12 has been shown to complex with several proteins to enable ribosome biogenesis and cell proliferation 17 . The mechanisms by which gene(s) at these three genomic regions confer increased risk of myocardial infarction remain to be defined.
Of note, the PHACTR1 locus may lead to myocardial infarction by directly promoting the development of atherosclerosis in the coronary arteries. In an independent GWAS for coronary artery calcification in 410,000 participants from six prospective cohort studies, PHACTR1 SNPs (along with chromosome 9p21 SNPs) are associated with coronary artery calcification at genome-wide significance (C.J. O'Donnell, National Heart, Lung and Blood Institute, personal communication).
Of the nine loci with convincing association evidence, the remaining two (19p13 near LDLR and 1p32 near PCSK9) relate to a causal risk factor for myocardial infarction: low-density lipoprotein (LDL) cholesterol. Common, low-frequency and/or rare mutations at LDLR and PCSK9 have previously been shown to influence LDL cholesterol and consequently affect risk for myocardial infarction [18] [19] [20] [21] [22] . We confirm that common variants near LDLR and PCSK9 are associated with risk for myocardial infarction. The specific alleles (LDLR rs1122608 and PCSK9 rs11206510) corresponding to higher risk for myocardial © 2009 Nature America, Inc. All rights reserved. Values with '±' are means ± s.d. The body-mass index is the weight in kilograms divided by the square of the height in meters.
a All cases and controls were of European ancestry. b Mean age at myocardial infarction for cases and at age of recruitment for controls. c Hypertension was defined as a previous diagnosis of hypertension, on antihypertensive therapy or with recorded systolic blood pressure Z 140 mmHg or diastolic blood pressure Z 90 mmHg. d Diabetes mellitus was defined as a previous diagnosis of diabetes or treatment with antidiabetic medications. e Hypercholesterolemia was defined as a previous diagnosis of hypercholesterolemia or treatment with lipid-lowering therapy.
infarction in the present study have recently been correlated with higher LDL cholesterol 4, 23, 24 .
To evaluate the cumulative effect of these nine SNPs on risk for myocardial infarction, we constructed a myocardial infarction genotype score comprised of the nine SNPs, modeling the number of risk alleles carried by each individual in the MIGen GWAS (stage 1). In logistic regression models including age, sex and principal components of ancestry, individuals in the top quintile of myocardial infarction genotype score had greater than twofold increased risk for myocardial infarction compared with bottom quintile (OR ¼ 2.23, 95% CI ¼ 1.89-2.63; P ¼ 1 Â 10 À21 ; Table 4 ).
Although this myocardial infarction genotype score confers risk of a magnitude comparable to other established risk factors such as plasma LDL cholesterol (hazard ratio ¼ 1.62, 95% CI ¼ 1.17-2.25 for top versus bottom quintile of LDL cholesterol as previously reported 25 ), further studies are required. The specific SNP set will need to include other recent discoveries for myocardial infarction such as the MRAS locus 26 as well as additional SNPs related to LDL cholesterol 24 . Nearly all SNPs related to LDL cholesterol affect risk for MI 4 . In addition, the score requires validation in independent studies, preferably those with a prospective cohort design 27 . Finally, gene-gene and gene-environment interactions need to be modeled if such interactions can be reproducibly documented.
Although the GWAS approach has met with some success in myocardial infarction, the confirmed myocardial infarction risk variants, in sum, explain a small fraction of the variance. The current myocardial infarction genotype score explains 2.8% of the variance in risk for early-onset myocardial infarction. Thus, we tested the hypothesis that systematic assessment of CNPs, © 2009 Nature America, Inc. All rights reserved. common and rare, might identify additional loci contributing to myocardial infarction. We first used the CANARY algorithm 11 to test 554 commonly segregating CNPs (41% frequency) for association with early-onset myocardial infarction in 2,783 cases and 2,865 controls that passed sample quality control for CNV analysis (see Methods). The estimated genomic control l for the entire set of CNPs was B1.23; for 316 CNPs with allele frequency greater than 5%, l was B1.05. We did not observe any CNP with evidence for association surpassing our prespecified threshold for replication of P o 0.001. In fact, the strongest association (P ¼ 0.002; Supplementary Table 3 online) did not pass the Bonferroni correction for 554 tests, let alone genome-wide significance for SNPs. A plot of the observed versus expected P value distribution did not show deviation from the null distribution ( Supplementary Fig. 1 online) .
To detect rare CNVs, we used Birdseye 11 and restricted analysis to autosomal deletions and duplications that were both rare (o1% frequency in our samples) and large (greater than 100 kb). After stringent quality control filtering (Supplementary Methods), the analysis included 5,955 individuals and 8,065 CNVs (39% deletions). The mean number of rare CNVs per individual was 1.35, and the median was 1.
Using the same methods recently described in a successful study of schizophrenia 28 , we evaluated case-control differences in rare CNVs across three parameters: the overall burden of rare CNVs genomewide, the number of genes overlapped by rare CNVs and the total kilobase extent of rare CNVs. Controlling for sample collection site, there were no case-control differences in genome-wide rare CNV rate (P ¼ 0.39), the number of genes intersected by rare CNVs (P ¼ 0.74) or the total kilobase extent of rare CNVs (P ¼ 0.77). Searching for specific loci with increased rates of rare CNVs in cases versus controls, we found only four regions that showed uncorrected P values o0.01; however, the lowest P value after correction for multiple testing was 0.96.
In summary, we screened common SNPs and CNVs (both common and rare) for association with early-onset myocardial infarction in a large sample. Our study suggests four main conclusions. First, there are at least nine regions that harbor common SNPs associated with myocardial infarction at genome-wide significance; three of these are newly described in this study. Second, the magnitude of risk conferred by a common variant bears no relationship to the potential biological value of the specific finding. For example, similarly to the newly identified loci, we find that common variants at LDLR and PCSK9 confer weak effects, and yet study of these two genes has yielded critical insights into atherosclerosis and myocardial infarction. Third, whereas the effects of individual SNPs are modest, the overall effect (in a comparison of extreme quintiles) is higher for a nine-SNP score (Btwofold increase in risk). This observation needs to be validated in additional studies. Finally, and in contrast to the positive results for genetic mapping of myocardial infarction via SNP analysis, we were unable to detect common or rare CNVs associated with risk for myocardial infarction.
The remaining inherited risk for myocardial infarction may be due to some combination of common SNPs for which we do not yet have © 2009 Nature America, Inc. All rights reserved. 
a For all studies except INTERHEART, where rs4675310 was substituted as a close to perfect proxy to rs6725887 (Hapmap CEU r 2 ¼ 1.0). b Odds ratio based on a fixed-effect-based metaanalysis of odds ratios. c P value based on a weighted z-score meta-analysis.
sufficient power, CNVs not measured in our analysis, rare point mutations, nonadditive interactions and epigenetic factors, among other possibilities. Approaches to further clarify the genetic architecture of myocardial infarction include larger-scale screens to identify more common SNPs, improved CNV maps and detection methods to enhance statistical power, and sequencing of myocardial infarction loci (and eventually all exons genome-wide) to discover low-frequency and rare variants. In parallel, mechanistic studies in cells, model organisms and humans that are focused on the nine validated loci should improve our understanding of the root causes of myocardial infarction, and consequently, enable better therapies for this disease.
METHODS
Study design and samples. We conducted a genetic association study with four stages as displayed in Figure 1 . Stage 1 consisted of MIGen, a collection of 2,967 cases of early-onset myocardial infarction (in men r50 y old or women r60 y old) and 3,075 age-and sex-matched controls free of myocardial infarction from six international sites: Boston and Seattle in the United States as well as Sweden, Finland, Spain and Italy ( Table 1) . At each site, myocardial infarction was diagnosed on the basis of autopsy evidence of fatal myocardial infarction or a combination of chest pain, electrocardiographic evidence of myocardial infarction, or elevation of one or more cardiac biomarkers (creatine kinase or cardiac troponin). The mean age at the time of myocardial infarction was 41 y among male cases and 47 y among female cases. We took forward SNPs into three stages of replication (stages 2-4; Fig. 1 ). We chose 1,441 SNPs to test in stage 2 on the basis of two criteria: (i) strength of statistical evidence in stage 1 (1,433 SNPs from loci with P o 10 À3 in stage 1) or (ii) belonging to one of eight reported loci from recent genome-wide association studies for CAD (a common SNP at or near 9p21.3, CXCL12, SMAD3, MTHFD1L, MIA3, CELSR2-PSRC1-SORT1, 2q36 and PCSK9) 3, 4 .
Stage 2 consisted of comparisons with four recently completed GWAS for myocardial infarction consisting of a symmetric effective sample size of up to 3,922 myocardial infarction cases and 3,922 controls. These studies included the Wellcome Trust Case Control Consortium Coronary Heart Disease study, German MI Family Study I, PennCATH and MedStar (Supplementary Methods and Supplementary Table 1 ). In each stage 2 study, the analysis was restricted to the phenotype of myocardial infarction with an age of onset threshold of o66 y for men or women. Although this age cutoff is slightly less restrictive than that used in stage 1, this cutoff is at or below the mean age of first myocardial infarction in the United States (65 y for men and 70 y for women) 5 .
We took forward 33 SNPs to stage 3, which consisted of genotyping an additional six studies with a symmetric effective sample size of up to 4,321 myocardial infarction cases and 4,321 controls. These six studies included Acute MI Gene Study/Dortmund Health Study, Verona Heart Study, Mid-America Heart Institute Study, Irish Family Study, German MI Family Study II and INTERHEART (European-ancestry samples) (Supplementary Methods and Supplementary Table 2) . Stage 3 comprised 25 SNPs with the best combined statistical evidence for myocardial infarction from stages 1 and 2 (P o 10 À5 ) and the eight previously reported SNPs discussed above. In each stage 3 study, the analysis was restricted to the phenotype of myocardial infarction, and in four of the six studies, an age-of-onset threshold was established at o66 y for men or women.
Thirteen SNPs were taken forward to stage 4, which consisted of association results from deCODE with a symmetric effective sample size of 1,503 cases of early-onset myocardial infarction and 1,503 controls (Supplementary Table 2 ). Stage 4 comprised five SNPs with the best combined statistical evidence from stages 1-3 and the eight previously reported SNPs. In the deCODE study, the analysis was restricted to cases with early-onset myocardial infarction (men o50 y old or women o60 y old). All participants in the 17 studies across stages 1, 2, 3 and 4 gave written informed consent in accordance with the guidelines of local ethical committees.
Genotyping. In stage 1, we studied 727,496 directly genotyped SNPs (Affymetrix 6.0 GeneChip) that passed quality-control filters, as described in the Supplementary Methods. In addition, we used these genotyped SNPs and the phased chromosomes from the HapMap CEU sample to impute genotypes for an additional 1,830,248 SNPs with MACH 1.0 software. In previous work, we have shown that imputation is accurate (average concordance rate of 97.9% between imputed and genotyped data for the same SNP) when using MACH 1.0 in samples of European ancestry with the HapMap CEU phased chromosomes as reference 29 .
Stage 2 studies were genotyped on either the Affymetrix GeneChip Human Mapping 500K Array Set or Affymetrix 6.0 GeneChip, and imputation of HapMap SNPs was done using either IMPUTE or MACH 1.0 software (Supplementary Table 1) .
In Stage 3, genotyping was attempted for 33 SNPs in five studies using the iPLEX MassARRAY platform (Sequenom). In the sixth study, German MI Family Study II, SNPs were genotyped using the Affymetrix 6.0 array (Supplementary Table 2) .
In Stage 4, the deCODE study samples were genotyped on Illumina Infinium HumanHap300 or HumanHap370 chips, and imputation of HapMap SNPs was done using IMPUTE software (Supplementary Table 2 ).
Association of individual SNP genotypes with myocardial infarction. In stage 1, we tested the association of early-onset myocardial infarction with a combined set of B2.5 million SNPs (directly genotyped and imputed with information content 40.5) using a logistic regression model that accounted for age, sex and study site. The estimated genomic control l 1000 was low at 1.01, suggesting little residual confounding due to population stratification. Regardless, association test statistics were corrected using the genomic control method; separate corrections were made for imputed SNPs (with information content 40.5) and genotyped SNPs. We tested imputed genotypes for association after accounting for uncertainty using the ''PROPER'' option in the SNPTest software package.
In addition, we evaluated an alternate method to account for potential confounding by population stratification within samples of European ancestry. We conducted principal-component analysis as implemented in PLINK software to define axes of ancestry within the six stage 1 studies 30 . The first two principal components separated individuals into clusters that matched studysite labels and revealed the well-known north-south cline in allele frequencies across Europe ( Supplementary Fig. 2 online) . Logistic regression analysis with the first two principal components as covariates (instead of study site) led to nearly identical association results (correlation in association statistics was 0.99). In stages 2 and 3, within each study, we examined the association of SNPs with myocardial infarction using logistic regression after adjustment for age and sex. In stage 4, SNPs were tested for association with early-onset myocardial infarction after adjustment for age and sex, with correction of association test statistics using the genomic-control method as previously described 2 .
We used two meta-analytic methods to summarize the statistical evidence for each SNP across stages 1-4. We combined odds ratios for a given reference allele on a logarithmic scale weighted by the inverse of their variances using a fixed-effects model. We also combined evidence for association solely on the © 2009 Nature America, Inc. All rights reserved. The nine validated myocardial infarction polymorphisms are as shown in Table 2 and Table 3 and include SLC5A3-MRPS6-KCNE2 rs9982601, PHACTR1 rs12526453, WDR12 rs6725887, 9p21.3 rs4977574, CXCL12 rs1746048, CELSR2-PSRC1-SORT1 rs646776, MIA3 rs17465637, LDLR rs1122608, and PCKS9 rs11206510. Risk of early-onset myocardial infarction was assessed in the 2,967 cases and 3,075 controls from stage 1.
basis of P values. For each study, we converted the two-sided P value to a z-statistic and assigned a sign to reflect the direction of the association given the reference allele. Each z-score was then weighted with the squared weights summing to 1 and each sample-specific weight being proportional to the square root of the effective number of individuals in the sample. We summed the weighted z-statistics across studies and converted the summary z-score to a two-sided P value. Statistical analyses were conducted using either PLINK software or in R.
Analyses of myocardial infarction genotype score, common CNVs and rare CNVs. Details for these analyses are provided in Supplementary Methods.
Statistical power. Given our inability to identify CNVs associated with myocardial infarction, we estimated our statistical power for such discovery. For common CNPs, we had 78% power to detect a CNP of 25% frequency and effect size of 1.20 at an alpha of 0.001 in 3,000 cases and 3,000 controls. For rare CNVs, we approximated by simulation the statistical power to detect a CNV with a population frequency for the deletion of 1/8,000 (that is, so it would be observed in 1/4,000 live births). We set the relative risk to 20.0 (the effect size seen for several rare variants associated with schizophrenia 28 ) and the population disease prevalence to 1/100. We simulated 10,000 datasets for 2,920 cases and 3,035 controls under this model. Using Fisher's exact test to account for small cell sizes, for a type 1 error rate of 0.01 (one-sided test) we had 97% power. The mean case frequency was B0.5%, and the mean control frequency was B0.02%. For a similarly rare variant but with a relative risk of 10.0, the average case frequency was B0.25% (control frequency still 0.02%) and power was lower at 54%. These simulations suggest that we had good power to detect loci with large effects, although this assumes perfect sensitivity and specificity for detection. For very large deletions, at least, we expect sensitivity to detect such CNVs would be high. However, we may have missed additional loci with CNVs that are less penetrant, rarer or smaller.
Note: Supplementary information is available on the Nature Genetics website.
